Aroa Biosurgery Posts NZ$84.7M Revenue and NZ$4.2M EBITDA in FY25

Robust Financial Performance in FY25

Aroa Biosurgery, a New Zealand-based leader in soft tissue regeneration, has delivered a strong financial performance for the fiscal year ending March 2025. The company reported total revenue of NZ$84.7 million, exceeding its guidance range of NZ$81–84 million. This growth was underpinned by solid sales momentum in key product lines including Endoform, Myriad, and Symphony, with Endoform sales growing 22% year-over-year and Myriad sales increasing by 24%.

Importantly, Aroa achieved a positive normalised EBITDA of NZ$4.2 million, surpassing the guided range of NZ$2–4 million. This marks a significant turnaround, reflecting improved operational efficiencies and a product gross margin that expanded to 86%, up 100 basis points from the prior year.

Strategic Product Growth and Market Penetration

The company’s growth strategy centers on expanding the reach of its Myriad product, which targets large complex wounds and lower limb salvage procedures. Myriad sales showed approximately 18% growth in the second half of FY25, supported by deeper penetration into hospital systems and integrated delivery networks (IDNs). Symphony, designed for complex chronic wounds, also demonstrated promising progress despite reimbursement challenges in physician offices, with a randomized controlled trial expected to conclude in Q3 2025 to support broader adoption.

Aroa’s partnership with TELA Bio continues to contribute to revenue, particularly through the OviTex reinforced tissue matrix portfolio, which has shown compelling clinical outcomes and low complication rates. The company’s regulatory approvals across 50 countries and over 7 million product applications underscore its global footprint and market potential.

Financial Health and Outlook

Cash management remains a strength, with a closing cash balance of NZ$22.0 million and positive operating cash flow recorded in the second half of FY25. The company also reduced its net cash outflows compared to prior periods, signaling improved financial discipline.

Looking ahead, Aroa has set FY26 guidance for total revenue between NZ$92 million and NZ$100 million, representing 10–20% growth on a constant currency basis. Normalised EBITDA is forecasted to rise to between NZ$5 million and NZ$8 million. Key milestones include converting a major Myriad IDN account, expanding clinical evidence through published studies, and securing Symphony reimbursement in physician offices, which could unlock new outpatient market opportunities.

Clinical Validation and Market Positioning

Clinical data continues to validate Aroa’s product efficacy, with peer-reviewed studies highlighting low infection and graft loss rates, rapid tissue revascularization, and minimal complications. These outcomes reinforce the company’s value proposition in complex wound care and soft tissue reconstruction, areas with a combined addressable market exceeding US$3 billion.

With a well-established product platform and a clear strategic focus on improving healing rates and reducing complications, Aroa is positioned to capitalize on growing demand for regenerative healing technologies in both hospital and outpatient settings.